Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates

Pharmacology

Volumn 56, Issue 2, 1998, Pages 57-70

  Kromer, W ^a   Kruger U ^a   Huber, R ^a   Hartmann, M ^a   Steinijans, V W ^a  

^a Byk Gulden ^*  (Germany)

Author keywords

Activation rates; Lansoprazole; Omeprazole; Pantoprazole; Prodrugs; Proton pump inhibitors; Rabeprazole; Substituted benzimidazoles; Tissue selectivity

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BENZIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; REACTIVE OXYGEN METABOLITE;

ACIDIFICATION; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LYSOSOME; MALE; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PARTITION COEFFICIENT; PH; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STOMACH PARIETAL CELL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANIMALS; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; DOGS; DRUG STABILITY; ENZYME INHIBITORS; GASTRIC ACID; GASTRIC MUCOSA; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; PROTEIN BINDING; PROTON PUMPS; RABBITS; SULFOXIDES;

EID: 2642674446     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028183     Document Type: Article

References (55)

1. Hersey SJ, Sachs G: Gastric acid secretion. Physiol Rev 1995; 75: 155-189.
2. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E: Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995;9:363-378.
3. Kromer W: Similarities and differences in the properties of substituted benzimidazoles: A comparison between pantoprazole and related compounds. Digestion 1995;56: 443-454.
4. +-ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
5. Silver IA, Murrills RJ, Etherington DJ: Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 1988;175:266-276.
6. Ohkuma S, Poole B: Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 1978;75:3327-3331.
7. Baron R, Neff L, Louvard D, Courtoy PJ: Cell-mediated extracellular acidification and bone resorption: Evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 1985;101:2210-2222.
8. Forgac M: Regulation of vacuolar acidification; in Clapham DE, Ehrlich BE (eds): Organellar Ion Channels and Transporters. New York, Rockefeller University Press, 1996, pp 121-131.
9. Rainer G, Krüger U, Klemm K: Synthese und physikalisch-chemische Eigenschaften von Lonazoiac-Ca, einem neuen Antiphlogistikum/ Antirheumatikum. Drug Res 1981; 31:649-655.
10. Weder HG, Schildknecht J, Lutz RA, Kesselring P: Determination of binding parameters from Scatchard plots. Eur J Biochem 1974;42:475-481.
11. +-ATPase inhibitor (BY 1023/SK&F 96022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up. J Chromatogr 1990;529:389-401.
12. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz HU: Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992;30:233-256.
13. +-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 1994;32:44-50.
14. Andersson T, Cederberg C, Regardh C-G, Skanberg I: Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 1990;39:195-197.
15. Notari RE: Biopharmaceutics and Clinical Pharmacokinetics: An Introduction, ed 4. New York. Marcel Dekker, 1987.
16. +)-ATPase inhibitor. Biochem Pharmacol 1990;39:1799-1806.
17. Simon WA, Sturm E, Kohl B: High pH selectivity for inhibition of acid secretion in isolated gastric glands by pantoprazole. Digestion 1991;49: 52-53.
18. Hatzelmann A, Ullrich V: Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur J Biochem 1987;169:175-184.
19. Kromer W, Kohl B: Pantoprazole sodium. Drugs Future 1990;15:801-804.
20. +)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity: The selection of pantoprazole as a clinical candidate. J Med Chem 1992;35:1049-1057.
21. Fitton A, Wiseman L: Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51:460-482.
22. Wilde MI, McTavish D: Omeprazole: An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91-132.
23. Barradell LB, Faulds D, McTavish D: Lansoprazole: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225-250.
24. Prous Science: E-3810. Drugs Future 1991;16:19-22.
25. +-ATPase inhibitors, omeprazole and E3810. J Biol Chem 1993;268:21553-21559.
26. Tomiyama Y, Morii M, Takeguchi N: Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994;48:2049-2055.
27. 2 receptor antagonist in the rat. Pharmacology 1990;41:333-337.
28. Kromer W, Postius S, Riedel R, Simon WA, Hanauer G, Brand U, Gönne S, Parsons ME: BY 1023/ SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J Pharmacol Exp Ther 1990;254:129-135.
29. Koop H, Kuly S, Flüg M, Schneider A, Rose K: Comparison of 24-h intragastric pH and 24-h gastrin profiles during therapy with the proton pump inhibitors pantoprazole and omeprazole. Gut 1994;35(suppl 4): A79.
30. Brunner G, Danz-Neeff H, Athmann C, Samayoa N: Comparison of pantoprazole (40 mg sid) versus omeprazole (40 mg sid) on mtragastric pH and serum gastrin in healthy volunteers. Can J Gastroenterol 1997;11(suppl A):S2.
31. Hartmann M, Theiss U, Huber R, Lühmann R, Bliesath H, Wurst W, Lücker PW: Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996;10:359-366.
32. Scholtz HE, Meyer BH, Luus HG: Comparison of the effects of lansoprazole, omeprazole and pantoprazole on 24-hour gastric pH in healthy males. S Afr Med J 1995;85: 915.
33. Valenzuela JE, Kogut DG, McCullough AJ, Colon Pagan JR, Shah U, Whipple J Gilde LR, Simon TJ: Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: A multicenter, randomized, double-blind study. Am J Gastroenterol 1996;91:2516-2522.
34. Lauritsen K, Rutgersson K, Bolling E, Brunner G, Eriksson S, Frison L, Galmiche JP, Thomson ABR, Walan A, Archambault AP, Gudjónsson H, Bailey R, Bianchi Porro G: Omeprazole 20 or 40 mg daily for healing of duodenal ulcer? A double-blind comparative study. Eur J Gastroenterol Hepatol 1992;4:995-1000.
35. Müller P, Simon B: Wird Omeprazol richtig dosiert? Münch Med Wochenschr 1996;48:802-804.
36. Myers BM, Prendergast FG, Holman R, Kuntz SM, LaRusso NF: Alterations in the structure, physico-chemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest 1991;88: 1207-1215.
37. Clague MJ, Urbé S, Aniento F, Gruenberg J: Vacuolar ATPase activity is required for endosomal carrier vesicle formation. J Biol Chem 1994;269:21-24.
38. Peace KE: Design and analysis considerations for safety data, particularly adverse events; in Sogliero-Gilbert G (ed): Drug Safety Assessment in Clinical Trials. New York, Marcel Dekker, 1993, pp 305-316.
39. +-ATPase inhibitor with an improved pH stability. Eur J Pharmacol 1992;218: 265-271.
40. +-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986; 38:123-125.
41. Zaidi M: Modularity of osteoclast behaviour and 'mode-specific' inhibition of osteoclast function. Biosci Rep 1990;10:547-556.
42. +-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:2l-25.
43. -245. Gut 1992;33:617-621.
44. Suzuki M, Mori M, Suzuki H, Asako H, Fukumura D, Miura S, Tsuchiya M: Omeprazole attenuates oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. Immunol Microbiol Inflamm Dis 1993;104:A787.
45. Suzuki M, Mon M, Fukumura D, Suematsu M, Miura S, Tsuchiya M: Omeprazole attenuates respiratory burst of human neutrophil by increasing intralysosomal pH. Immunol Microbiol Inflamm Dis 1994; 106:A779.
46. Aybay C, Imir T, Okur H: The effect of omeprazole on human natural killer cell activity. Gen Pharmacol 1995;26:1413-1418.
47. Scaringi L, Cornacchione P, Fettucciari K, Rosati E, Rossi R, Marconi P, Capodicasa E: Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 1996;44: 204-214.
48. Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, Ishii H: Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radical Biol Med 1996;21:727-731.
49. Capodicasa E, Ciaccio V, Corazzi F, De Bellis F, Bucaneve G, Ficola F, Pelli MA: Reduced 'ex-vivo' production of Superoxide anion by polymorphonuclear leukocytes during therapy with omeprazole: A pharmacologic effect? Minerva Gastroenterol Dietol 1994;40:105-111.
50. Roos D: The involvement of oxygen radicals in microbicidal mechanisms of leukocytes and macrophages. Klin Wochenschr 1991;69: 975-980.
51. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE: Free radicals and phagocytic cells. FASEB J 1995; 9:200-209.
52. Watson F, Robinson JJ, Edwards SW; Sequential phospholipase activation in the stimulation of the neutrophil NADPH oxidase. FEMS Microbiol Immunol 1992;105:239-248.
53. Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F: Antioxidant properties of omeprazole. FEBS Lett 1996;382:189-192.
54. Kountouras J, Boura P, Apostolides G, Zaharioudaki E, Tsapas G: In vivo effect of omeprazole on HLADR expression and the monocyte-macrophage function in patients with duodenal ulcer disease. Immunopharmacol Immunotoxicol 1994; 16:437-448.
55. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N: Pharmaco-kinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994;32:466-473.